ClinicalTrials.gg
Enrolling by invitationNCT06623708Updated Nov 10, 2026

SMARTCLOTH. Design, Implementation and Study of the Effectiveness and Usability of a Digital Tablecloth for Self-management of Diet in Diabetic Patients.

An interventional study of SMARTCLOTH in Diabetes Mellitus Type 2 and Diabetes Mellitus Type 1, sponsored by Maimónides Biomedical Research Institute of Córdoba. Enrolling by invitation at 5 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Maimónides Biomedical Research Institute of Córdoba · Not applicable, Interventional, and Treatment

How we know

Updated Nov 10, 2026Start date movedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain — 44 open to participants now, 55 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · Spain.

Planned enrollment
326th of 383
90 · median 484
Started
2025
with 17 others
No phase
77 of 429
17 open now
Primary completion
2027-10
later than 28 of 54 live
Registered
380th of 429
by date

Among the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, this one is the 326th largest by planned enrollment of the 383 interventional ones that give a count, is one of 18 that started in 2025, is one of 77 with no phase, reaches primary completion later than 28 of the 54 other live ones, and was the 380th registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

44 of the 429 studies in Diabetes Mellitus, Type 2 with a site in Spain are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 429 studies in Diabetes Mellitus, Type 2 with a site in Spain, or all of them as a file.
02

Study summary

The objective of this clinical trial is to know the usability and efficacy of SMARTCLOTH for better control and adherence to the dietary patterns recommended to patients with diabetes, both the portion diet system (more common for cases of Diabetes Mellitus type 1 -DM1-), and the plate method (more recommended in cases of Diabetes Mellitus type 2-DM2-). The main questions are:

  • Does the use of SMARTCLOTH improve glycemic control in patients with diabetes mellitus?
  • Do patients with diabetes mellitus find SMARTCLOTH useful in their daily lives?

The researchers will compare changes over 3 months in variables related to glycemic control in two groups, one using SMARTCLOTH (intervention group) and the other following standard recommendations (control group). To do so, participants will have to:

  • Use SMARTCLOTH for 3 months or follow the recommendations they receive from their referring health professionals.
  • Come back after three months for a check-up of the chosen variables.
  • The experimental group should contact the investigators in case the hardware has any problems.
03

Conditions studied

  • Diabetes Mellitus Type 2
  • Diabetes Mellitus Type 1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Subjects with type 1 and 2 diabetes (eligible population) aged between 18 and 70 years with disease progression not exceeding 15 years and greater than 7.5.

Exclusion Criteria:

  • Degree of dependence (physical or psychological) that makes it impossible for them to perform autonomous self-care of the dietary-nutritional regimen.
  • Oncological or disease, chronic renal insufficiency, transplant patients and others that alter the values of the result variables or may constitute a confounding factor.
  • Other diseases that entail surgical interventions or hospital admissions that make it impossible to follow up the study.
  • Patients with complications due to the evolution of the diabetic pathology: retinopathy, nephropathy, polyneuropathy, ischemic heart disease, as well as other micro and macrovascular complications derived from the same and already recorded in the patient.
  • Those subjects subjected to specific dietary regimes such as celiac disease, lactose intolerant, etc.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • No intervention
    Control

    This group of participants should follow the general recommendations for the management of Type 1 or Type 2 Diabetes.

  • Experimental
    SMARTCLOTH

    This group will use SMARTCLOTH for 3 months.

    Device: SMARTCLOTH

Interventions

  • DeviceSMARTCLOTH

    The intervention consists of using SMARTCLOTH. This device makes it possible to monitor dietary intake throughout the day and record it in a database that, through a website, allows to track it. SMARTCLOTH is a digital tablecloth consisting of a scale, several buttons and a screen. The device allows weighing the food to be consumed and recording its nutritional value (macronutrients in grams, macronutrient servings and kilocalories). The latter is achieved because SMARTCLOTH allows the patient to select to which food group the food being weighed belongs, increasing the accuracy of the nutritional estimation.

06

What researchers measure

Primary outcomes

  1. glycated hemoglobin

    The test shows an average of the blood sugar level over the past 90 days and represents a percentage. The test can also be used to diagnose diabetes

    Time frame: From enrollment to the end of treatment at 3 months

07

Study locations

5 sites
  • Ugc Centro
    Córdoba, Andalusia 14001, Spain
  • Ugc Lucano
    Córdoba, Andalusia 14003, Spain
  • Ugc Aeropuerto
    Córdoba, Andalusia 14004, Spain
  • Ugc Fuensanta
    Córdoba, Andalusia 14010, Spain
  • Ugc La Carlota
    Córdoba, Andalusia 14100, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Oct 2027, 29 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 29 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: start Oct 2024 → May 2025, primary completion Dec 2024 → Oct 2027 and completion Jan 2025 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2024
First posted
Oct 2, 2024
StartActual
May 2, 2025was Oct 2024
Primary completionEst.
Oct 2027was Dec 2024
CompletionEst.
Oct 2027was Jan 2025
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added, 5 sites removed
Show 5 added (5 Spain)
  • Ugc Centro · Córdoba, Spain
  • Ugc Lucano · Córdoba, Spain
  • Ugc Aeropuerto · Córdoba, Spain
  • Ugc Fuensanta · Córdoba, Spain
  • Ugc La Carlota · Córdoba, Spain
Show 5 removed
  • Ugc Centro · Córdoba, Spain
  • Ugc Lucano · Córdoba, Spain
  • Ugc Aeropuerto · Córdoba, Spain
  • Ugc Fuensanta · Córdoba, Spain
  • Ugc La Carlota · Córdoba, Spain
Nov 10, 2026
Start date
Oct 2024→May 2, 2025 (actual)
Nov 10, 2026
Primary completion
Dec 2024→Oct 2027
Nov 10, 2026
Study completion
Jan 2025→Oct 2027
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    5 sites added, 5 sites removed
    Show 5 added (5 Spain)
    • Ugc Centro · Córdoba, Spain
    • Ugc Lucano · Córdoba, Spain
    • Ugc Aeropuerto · Córdoba, Spain
    • Ugc Fuensanta · Córdoba, Spain
    • Ugc La Carlota · Córdoba, Spain
    Show 5 removed
    • Ugc Centro · Córdoba, Spain
    • Ugc Lucano · Córdoba, Spain
    • Ugc Aeropuerto · Córdoba, Spain
    • Ugc Fuensanta · Córdoba, Spain
    • Ugc La Carlota · Córdoba, Spain
    Start date Oct 2024→May 2, 2025 (now actual)
    Primary completion Dec 2024→Oct 2027
    Study completion Jan 2025→Oct 2027
    + 2 other changes: verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06623708
Lead sponsor
Maimónides Biomedical Research Institute of Córdoba
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
May 2, 2025
Primary completion
Oct 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Nov 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion